Key result
Meloxicam demonstrated equal efficacy and safety advantages compared to nonselective NSAIDs, with high safety regarding gastrointestinal complications competitive with celecoxib.
Why the study?
Does meloxicam provide equal efficacy and improved safety compared to nonselective NSAIDs and celecoxib in patients with gastrointestinal and cardiovascular risk factors?
Does meloxicam provide equal efficacy and improved safety compared to nonselective NSAIDs and celecoxib in patients with gastrointestinal and cardiovascular risk factors?
Meloxicam offers a favorable safety profile, particularly regarding gastrointestinal complications, with efficacy comparable to nonselective NSAIDs.
May favor meloxicam in GI-risk patients; leaves open prospective RCTs versus celecoxib in high CV-risk cohorts.
The paper gives the results of randomized clinical trials and the use of meloxicam in real clinical practice in patients having risk factors for unfavorable gastrointestinal and cardiovascular events. It shows the advantages of meloxicam in safety and equal efficacy as compared with those of nonselective nonsteroidal anti-inflammatory drugs, and its high safety in causing gastrointestinal complications, which is highly competitive with that of celecoxib. Clinical and experimental findings suggesting that meloxicam has no negative effect on the cartilage are presented.
No takes yet. Share an insight, caveat, or question.
Natalia Vladimirovna Chichasova (2012) conducted a review in Patients having risk factors for unfavorable gastrointestinal and cardiovascular events. Meloxicam vs. Nonselective nonsteroidal anti-inflammatory drugs and celecoxib was evaluated on Efficacy and safety (gastrointestinal complications). Meloxicam demonstrated equal efficacy and safety advantages compared to nonselective NSAIDs, with high safety regarding gastrointestinal complications competitive with celecoxib.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: